Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs
Tóm tắt
Pituitary neuroendocrine tumors (PitNETs) lacking lineage affiliation are termed “null cell” PitNETs (NCTs). NCTs are characterized as being immunonegative for pituitary hormones as well as transcription factors. We analyzed the ultrastructure and immunohistochemistry of six hormone-negative and transcription factor (TPIT, PIT1, SF1)-negative PitNETs, with less than 1% immunoreactive cells. Histologically, three cases presented a perivascular pattern and pseudorosettes; the other three showed a solid pattern with oncocytic changes. Electron microscopic examination revealed poorly differentiated tumor cells with sparsely scattered secretory granules and intracellular organelles in all null cell tumors when compared with hormone-positive PitNETs. Two cases harbored a honeycomb Golgi (HG) structure, and three oncocytic tumors showed mitochondrial accumulation. The two HG cases were immunopositive for newly obtained TPIT (CL6251) and showed some adrenocorticotropic hormone-positive cells, while the remaining four were diffusely immunopositive for GATA3, with two SF1-positive cases identified in subsequent immunostaining. Thus, these six cases may be classified as two sparsely granulated corticotroph PitNETs, two gonadotroph PitNETs with SF1 re-staining, and two likely gonadotroph PitNETs with GATA3 immunostaining. No “true NCT” was detected among 1071 PitNETs, demonstrating the importance of precise diagnosis following the most recent criteria to improve therapeutic success.
Tài liệu tham khảo
Kovacs K, Horvath E, Ryan N et al (1980) Null cell adenoma of the human pituitary. Virchows Archiv A Pathol Anat Histol 387:165–174
Lloyd RV, Osamura RY, Klöppel G (eds) (2017) Pituitary adenoma. In WHO classification of tumours of endocrine organs, 4th edn. IARC, Lyon, pp 12–40
Nishioka H, Inoshita N, Mete O et al (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26:349–355
Asa SL, Mete O, Perry A et al (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33:6–26
Almeida JP, Stephens CC, Eschbacher JM et al (2019) Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary 22(5):514–519
Kovacs K, Horvath E (1986) Tumors of the pituitary gland. Atlas of Tumor Pathology, Fascicle 21. 2nd Series. AFIP, Washington
Sano T, Mader R, Asa SL et al (2003) “Honeycomb Golgi” in pituitary adenomas: not a marker of gonadotroph adenomas. Endocr Pathol 14:363–368
Horvath E, Kovacs K (1984) Gonadotroph adenomas of the human pituitary: sex-related fine-structural dichotomy. A histologic, immunocytochemical, and electron-microscopic study of 30 tumors. Am J Pathol 117:429–440
Niveiro M, Aranda FI, Payá A et al (2004) Oncocytic transformation in pituitary adenomas: immunohistochemical analyses of 65 cases. Arch Pathol Lab Med 128:776–780
Sjöstedt E, Bollerslev J, Mulder J et al (2017) A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol 134:675–677
Sano T, Yamada S (1994) Histologic and immunohistochemical study of clinically non-functioning pituitary adenomas: special reference to gonadotropin-positive adenomas. Pathol Int 44:697–703
Al-Brahim NY, Asa SL (2006) My approach to pathology of the pituitary gland. J Clin Pathol 59:1245–1253
Trouillas J, Jaffrain-Rea ML, Vasiljevic A et al (2020) How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 12:514
Dottermusch M, Schüller U, Hagel C et al (2023) Unveiling the identities of null cell tumours: epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification. Neuropathol Appl Neurobiol 49:e12870